Niagen Bioscience rises on U.S. patent for injectable NAD+ booster

Niagen Bioscience

25/02/2026 14:10

** Shares of drugmaker Niagen Bioscience NAGE.O rise 3.3% to $5.28 premarket

**  Co says it secured a new U.S. patent covering intravenous and injectable versions of its NAD+-boosting ingredient, Niagen

**  Niagen is a form of nicotinamide riboside, a vitamin B3 derivative used to raise NAD+ levels, which helps support cellular energy and repair, per co

**  Co says patent protection runs to 2044 and gives exclusive rights to offer faster and more comfortable NAD+ infusions at clinics

**  Niagen IV is already offered at more than 1,200 clinics; co says new formulation delivers NAD+ more efficiently with fewer side effects, co says

** Shares up ~20% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))